Ivax Diagnostics Delays Filing 3Q Report
16th Nov 2006, 08:21 GMT
Ivax Diagnostics which makes medical and lab test products, said it filed notice with the SEC that its Q3 report will be late.
Ivax Diagnostics Delays Filing 3Q Report related news:
- Fossil delays 3Q filing — bizjournals.com Banking & Financial Services:Commercial Banking headlines
- Mills delays filing quarterly report — bizjournals.com Business Services:Accounting & Consulting headlines
- Toreador delays 10-Q filing — Latest news from Dallas Business Journal
- GTSI misses deadline for filing 3Q financials — Washington Technology Resellers & Distributors News
- TMNG will review stock options, delays quarterly filing — Latest news from Kansas City Business Journal
- Orbital delays financial report — bizjournals.com Business Services:Employee Compensation & Benefits headlines
- iBasis receives Nasdaq delisting notice — Latest news from Boston Business Journal
- "Residual Delays" on the L — Gothamist
- UnitedHealth to Delay Quarterly Filing — Insurance/ Managed Care News from StratCenter.com
- World Air Holdings Delays Filing 2006 Third Quarter Financial Results — PR Newswire: All Releases
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
- FermaVir's Founder and Board Member Professor Chris McGuigan receives the Royal Society of Chemistry's Award for Medicinal Chemistry